Tesamorelin Alternatives Compared
| Tesamorelin | Egrifta (tesamorelin) | Myalept (metreleptin) |
|
|---|
| Tesamorelin | Egrifta (tesamorelin) | Myalept (metreleptin) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Lipodystrophy. Tesamorelin may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Lipodystrophy. Egrifta may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Lipodystrophy. Myalept may also be used for purposes not listed in this medication guide. |
Related suggestions Lipodystrophy
|
|||||||||||||||
| More about Tesamorelin | More about Egrifta (tesamorelin) | More about Myalept (metreleptin) | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Tesamorelin has an average rating of 6.6 out of 10 from a total of 22 ratings on Drugs.com. 45% of reviewers reported a positive effect, while 14% reported a negative effect. |
Egrifta has an average rating of 6.6 out of 10 from a total of 20 ratings on Drugs.com. 45% of reviewers reported a positive effect, while 15% reported a negative effect. |
Be the first to share your experience with this drug. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
|
View all Tesamorelin side effects |
View all Egrifta side effects |
View all Myalept side effects |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Egrifta prices |
View all Myalept prices |
||||||||||||||||
| Dosage Forms | ||||||||||||||||||
|
N/A |
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Egrifta |
N/A |
N/A |
||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
|
0.63 hours |
0.63 hours |
4.7 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 48 drugs are known to interact with Tesamorelin:
|
A total of 48 drugs are known to interact with Egrifta:
|
A total of 203 drugs are known to interact with Myalept:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
N/A |
N/A |
February 24, 2014 |
||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||
|
N/A |
||||||||||||||||||
| More Information | ||||||||||||||||||
| Patient Resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.